Menu
Summary:
Metastatic renal cell carcinoma (mRCC) is difficult to treat, even with the encouraging combination of nivolumab and ipilimumab immunotherapy drugs. Only 42% of patients respond to this therapy, and recent studies suggest an imbalance in patient’s gut microbiome may play a role in this poor response. Dr. Pal and his team are testing adding a probiotic, CBM588, to the standard combination immunotherapy treatment in hopes that this probiotic helps to balance the gut microbiome and increase the effectiveness of the immunotherapy treatment for patients with mRCC.
Don't miss out on exciting news, helpful resources, and impactful stories delivered to your inbox each month.
20 North Martingale Road
Suite 180
Schaumburg, IL 60173
888-221-CURE
© 2022 Gateway for Cancer ResearchSM